Montelukast Farmax

Montelukast, the active ingredient in Montelukast Farmax, is a leukotriene receptor antagonist presented as a tablet for oral use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelukast Farmax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene receptor antagonist used to manage respiratory conditions mediated by leukotrienes.

- Asthma: reduces frequency of wheezing episodes and improves lung function. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching. - Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Abdominal pain - Cough - Dyspepsia - Fatigue - Nausea

Serious or Rare Side Effects: - Allergic reactions such as angioedema or anaphylaxis - Mood changes, including suicidal thoughts - Elevated liver enzymes - Stevens‑Johnson syndrome - Neutropenia - Eosinophilic granulomatosis with polyangiitis

When prescribing Montelukast, consider the following precautions.

- Liver function: monitor hepatic enzymes in patients with liver disease. - Psychiatric history: observe for mood alterations or suicidal ideation. - Severe asthma: do not use as a rescue medication for acute attacks. - Hypersensitivity: avoid in patients with known allergy to montelukast or excipients. - Renal impairment: consider dose adjustment and monitor renal function. - Store at ambient temperature: keep below 25°C, protect from moisture and store in original packaging.

Montelukast may interact with other medicines; review patient medication lists.

Major Interactions (Avoid): - Phenobarbital: induces metabolism, reducing montelukast plasma levels. - Rifampin: strong enzyme inducer that may decrease therapeutic effect. - Other potent CYP3A4 inducers: may lower drug exposure.

Moderate Interactions (Monitor Closely): - Fluconazole: CYP3A4 inhibitor that can increase montelukast concentrations. - Zafirlukast: additive leukotriene blockade may increase risk of side effects. - Beta‑agonists: concurrent use may require monitoring for enhanced bronchodilation.